| Revised response criteria for malignant lymphoma BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ... Journal of clinical oncology 25 (5), 579-586, 2007 | 5410 | 2007 |
| FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 R Boellaard, R Delgado-Bolton, WJG Oyen, F Giammarile, K Tatsch, ... European journal of nuclear medicine and molecular imaging 42, 328-354, 2015 | 3076 | 2015 |
| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ... Journal of clinical oncology 25 (5), 571-578, 2007 | 1687 | 2007 |
| FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 R Boellaard, MJ O’Doherty, WA Weber, FM Mottaghy, MN Lonsdale, ... European journal of nuclear medicine and molecular imaging 37, 181-200, 2010 | 1622 | 2010 |
| Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study AT van Oosterom, I Judson, J Verweij, S Stroobants, ED di Paola, ... The Lancet 358 (9291), 1421-1423, 2001 | 1603 | 2001 |
| Imaging biomarker roadmap for cancer studies JPB O'connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ... Nature reviews Clinical oncology 14 (3), 169-186, 2017 | 1115 | 2017 |
| Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO JY Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, ... Annals of Oncology 16 (4), 566-578, 2005 | 1020 | 2005 |
| Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma P Flamen, A Lerut, E Van Cutsem, W De Wever, M Peeters, S Stroobants, ... Journal of Clinical Oncology 18 (18), 3202-3210, 2000 | 741 | 2000 |
| 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (GlivecŪ) S Stroobants, J Goeminne, M Seegers, S Dimitrijevic, P Dupont, J Nuyts, ... European journal of cancer 39 (14), 2012-2020, 2003 | 686 | 2003 |
| Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is … K Spaepen, S Stroobants, P Dupont, S Van Steenweghen, J Thomas, ... Journal of Clinical Oncology 19 (2), 414-419, 2001 | 615 | 2001 |
| Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose–Positron Emission Tomography Scan in Non–Small-Cell Lung Cancer … JF Vansteenkiste, SG Stroobants, PJ Dupont, PR De Leyn, EK Verbeken, ... Journal of Clinical Oncology 17 (10), 3201-3206, 1999 | 571 | 1999 |
| Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. JF Vansteenkiste, SG Stroobants, PR De Leyn, PJ Dupont, J Bogaert, ... Journal of Clinical Oncology 16 (6), 2142-2149, 1998 | 558 | 1998 |
| Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma K Spaepen, S Stroobants, P Dupont, P Vandenberghe, J Thomas, ... Annals of Oncology 13 (9), 1356-1363, 2002 | 541 | 2002 |
| Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch D Blockmans, S Stroobants, A Maes, L Mortelmans The American journal of medicine 108 (3), 246-249, 2000 | 438 | 2000 |
| Simultaneous maximum a posteriori reconstruction of attenuation and activity distributions from emission sinograms J Nuyts, P Dupont, S Stroobants, R Benninck, L Mortelmans, P Suetens IEEE transactions on medical imaging 18 (5), 393-403, 1999 | 420 | 1999 |
| The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer LJ Vanuytsel, JF Vansteenkiste, SG Stroobants, PR De Leyn, W De Wever, ... Radiotherapy and Oncology 55 (3), 317-324, 2000 | 378 | 2000 |
| Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR … G Gebhart, LE Lamberts, Z Wimana, C Garcia, P Emonts, L Ameye, ... Annals of oncology 27 (4), 619-624, 2016 | 375 | 2016 |
| Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non … CJ Hoekstra, SG Stroobants, EF Smit, J Vansteenkiste, H Van Tinteren, ... Journal of clinical oncology 23 (33), 8362-8370, 2005 | 321 | 2005 |
| Clinical value of [18F] fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin D Blockmans, D Knockaert, A Maes, J De Caestecker, S Stroobants, ... Clinical Infectious Diseases 32 (2), 191-196, 2001 | 317 | 2001 |
| Additional Value of Whole-Body Positron Emission Tomography With Fluorine-18-2-Fluoro-2-deoxy-d-glucose in Recurrent Colorectal Cancer P Flamen, S Stroobants, E Van Cutsem, P Dupont, G Bormans, ... Journal of clinical oncology 17 (3), 894-894, 1999 | 306 | 1999 |
